Is It Feasible to Use CMV-Specific T-Cell Adoptive Transfer as Treatment Against Infection in SOT Recipients?

During the last decade, many studies have demonstrated the role of CMV specific T-cell immune response on controlling CMV replication and dissemination. In fact, it is well established that transplanted patients lacking CMV-specific T-cell immunity have an increased occurrence of CMV replication epi...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in immunology Vol. 12; p. 657144
Main Authors: García-Ríos, Estéfani, Nuévalos, Marcos, Mancebo, Francisco J, Pérez-Romero, Pilar
Format: Journal Article
Language:English
Published: Switzerland Frontiers Media S.A 23-04-2021
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:During the last decade, many studies have demonstrated the role of CMV specific T-cell immune response on controlling CMV replication and dissemination. In fact, it is well established that transplanted patients lacking CMV-specific T-cell immunity have an increased occurrence of CMV replication episodes and CMV-related complications. In this context, the use of adoptive transfer of CMV-specific T-cells has been widely investigated and applied to Hematopoietic Stem Cell Transplant patients and may be useful as a therapeutic alternative, to reconstitute the CMV specific T-cell response and to control CMV viremia in patients receiving a transplantation. However, only few authors have explored the use of T-cell adoptive transfer in SOT recipients. We propose a novel review in which we provide an overview of the impact of using CMV-specific T-cell adoptive transfer on the control of CMV infection in SOT recipients, the different approaches to stimulate, isolate and expand CMV-specific T-cells developed over the years and a discussion of the possible use of CMV adoptive cellular therapy in this SOT population. Given the timeliness and importance of this topic, we believe that such an analysis will provide important insights into CMV infection and its treatment/prevention.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Reviewed by: Britta Eiz-Vesper, Hannover Medical School, Germany; Susan Prockop, Memorial Sloan Kettering Cancer Center, United States
This article was submitted to Viral Immunology, a section of the journal Frontiers in Immunology
Edited by: Marco Antonio Moro-García, Central University Hospital of Asturias, Spain
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2021.657144